Who makes Burosumab Injection [Crysvita]?

Burosumab Injection [Crysvita] is developed by Yale University.

What development phase is Burosumab Injection [Crysvita] in?

Burosumab Injection [Crysvita] is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Burosumab Injection [Crysvita]

Yale University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Burosumab Injection [Crysvita]
Also known as	Crysvita
Sponsor	Yale University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Burosumab Injection [Crysvita] CI brief — competitive landscape report
Burosumab Injection [Crysvita] updates RSS · CI watch RSS
Yale University portfolio CI